Biotinylated red blood cell surface proteins (BioRBC)

Biotinylated red blood cell surface proteins represent a synthetic therapeutic and diagnostic target system created by the covalent conjugation of biotin (Vitamin B7) to the primary amines of erythrocyte membrane proteins, most notably Band 3 (Anion exchanger 1) and Glycophorin A. This modification transforms the red blood cell (RBC) into a versatile platform for both diagnostic and therapeutic applications. In clinical diagnostics, biotinylated RBCs (BioRBCs) serve as a safe, non-radioactive alternative to chromium-51 for the precise measurement of RBC volume, survival, and kinetics, which is essential for managing hemolytic anemias and monitoring long-term glycemic control in diabetes. Therapeutically, the biotin moieties act as high-affinity docking sites for avidin- or streptavidin-fused proteins, allowing for the "hitching" of drugs to the RBC surface. This approach exploits the long circulatory lifespan of erythrocytes to dramatically extend the half-life of therapeutic enzymes, such as asparaginase for leukemia or fibrinolytics for thrombosis, while protecting the cargo from premature clearance and degradation. However, the clinical use of this system requires monitoring for immunogenicity, as a subset of patients may develop anti-biotin or anti-BioRBC antibodies that can lead to accelerated clearance of the modified cells.

Other names

Biotinylated erythrocytesBiotin-labeled red blood cellsBioRBCBiotin-RBCBiotinylated red blood cells

The biotin moieties serve as high-affinity anchors for avidin- or streptavidin-conjugated therapeutic agents, enabling the use of red blood cells as long-circulating carriers to improve pharmacokinetics and protect the cargo from degradation.